Healing & Recovery

ARA-290

ARA-290 / Cibinetide

Tissue-protective EPO-derived peptide without red-cell effects

Research Status: Investigational; Phase II clinical data Cibinetide pHBSP
Mechanism of Action

How it works

ARA-290 mimics a portion of EPO that activates the innate repair receptor (an EPOR/CD131 complex) on injured tissue. This drives anti-inflammatory and tissue-repair signaling without stimulating red-blood-cell production.

Areas of Research

What the research explores

In published research, ARA-290 has been studied in connection with the following. These describe findings reported in the literature — not approved uses, claims, or outcomes to expect.

  • Activates tissue-repair signaling without raising hematocrit
  • Studied for neuropathic pain and small-fiber neuropathy
  • Investigated in sarcoidosis-related neuropathy
  • Anti-inflammatory in injury models
  • Researched for metabolic and wound-healing markers
Research Highlight

Phase II trials in sarcoidosis patients with small-fiber neuropathy reported improvements in pain and nerve-fiber measures over placebo.

Safety Profile

Adverse events & gaps

Investigational. Notably designed to avoid EPO's thrombotic/hematologic effects. Well tolerated in trials.



Stay Informed on
Peptide Research

Research summaries, newly documented peptides, and clinical trial updates delivered to your inbox.

No spam. Unsubscribe at any time.